Literature DB >> 11360997

Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase.

E Bodur1, A N Cokuğraş, E F Tezcan.   

Abstract

Benactyzine and drofenine are widely used anticholinergic drugs. Benactyzine is used to treat organophosphate poisoning and drofenine acts on smooth muscle to stop muscle spasms. Both of these drugs are esters. After they enter the bloodstream, they will interact with butyrylcholinesterase (BChE; acylcholine acyl hydrolase: EC 3.1.1.8), which has an ability to hydrolyze a wide variety of esters. Therefore, the kinetic analysis of their inhibitory effects on human serum BChE was examined using butyrylthiocholine as substrate. Both drugs were competitive inhibitors of BChE and the Ki values of benactyzine and drofenine were calculated to be 0.010 +/- 0.001 and 0.003 +/- 0.000 mM, respectively, using the Systat (version 5.03, 1991) nonlinear regression analysis software package. According to these parameters, drofenine is a more potent competitive inhibitor of BChE than benactyzine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360997     DOI: 10.1006/abbi.2000.2188

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Partial purification and characterization of soluble isoform of butyrylcholinesterase from rat intestine.

Authors:  Ozlem Yildiz; Ebru Bodur; A Neşe Cokuğraş; Nazmi Ozer
Journal:  Protein J       Date:  2004-02       Impact factor: 2.371

2.  Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle.

Authors:  Henry C Ou; Lisa L Cunningham; Shimon P Francis; Carlene S Brandon; Julian A Simon; David W Raible; Edwin W Rubel
Journal:  J Assoc Res Otolaryngol       Date:  2009-02-25

3.  Decreased activity of butyrylcholinesterase in blood plasma of patients with chronic obstructive pulmonary disease.

Authors:  Paulina Sicinska; Bozena Bukowska; Aneta Pajak; Aneta Koceva-Chyla; Tadeusz Pietras; Piotr Nizinkowski; Paweł Gorski; Maria Koter-Michalak
Journal:  Arch Med Sci       Date:  2016-06-20       Impact factor: 3.318

4.  YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity.

Authors:  Congrui Zhu; Samir El Qaidi; Peter McDonald; Anuradha Roy; Philip R Hardwidge
Journal:  Pathogens       Date:  2021-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.